详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Tumor angiogenesis and anti-angiogenic therapy

文献详情

资源类型：

Pubmed体系：

收录情况： ◇ 统计源期刊 ◇ CSCD-C ◇ 卓越：领军期刊 ◇ 中华系列

作者：

机构： [1]Department of Pancreatic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China. [2]Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm 17177, Sweden. [3]Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vison and Brain Health), School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China. [4]Cancer Institute, the First Clinical Medical College, Xuzhou Medical University, Xuzhou, Jiangsu 221000, China. [5]Department of Cellular and Genetic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.

出处：

DOI：

ISSN：

关键词： Angiogenesis Cancer Angiogenesis inhibitors Angiogenic factors Vascular endothelial growth factors Cancer therapy Combined modality therapy

摘要：

Anti-angiogenic drugs (AADs), which mainly target the vascular endothelial growth factor-A signaling pathway, have become a therapeutic option for cancer patients for two decades. During this period, tremendous clinical experience of anti-angiogenic therapy has been acquired, new AADs have been developed, and the clinical indications for AAD treatment of various cancers have been expanded using monotherapy and combination therapy. However, improvements in the therapeutic outcomes of clinically available AADs and the development of more effective next-generation AADs are still urgently required. This review aims to provide historical and perspective views on tumor angiogenesis to allow readers to gain mechanistic insights and learn new therapeutic development. We revisit the history of concept initiation and AAD discovery, and summarize the up-to-date clinical translation of anti-angiogenic cancer therapy in this field.Copyright © 2024 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2024]版：

无

最新[2023]版：

大类 | 3 区医学

小类 | 3 区医学：内科

第一作者：

第一作者机构： [1]Department of Pancreatic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.

共同第一作者：

通讯作者：

通讯机构： [2]Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm 17177, Sweden.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Novel dual inhibitors targeting CDK4 and VEGFR2 synergistically suppressed cancer progression and angiogenesis. [2]食管癌个体化综合治疗的研究 [3]Investigational drugs for nasopharyngeal carcinoma [4]老年乳腺癌新辅助治疗病理完全缓解的预测因素分析 [5]免疫检查点抑制剂联合抗血管生成治疗中晚期肝癌安全性和临床效果的meta分析 [6]乳腺癌相关成纤维细胞：乳腺癌治疗的新靶点 [7]MOF@COF nanocapsule for the enhanced microwave thermal-dynamic therapy and anti-angiogenesis of colorectal cancer. [8]Pull the plug: Anti-angiogenesis potential of natural products in gastrointestinal cancer therapy [9]Tumor Targeted Curcumin Delivery by Folate-Modified MPEG-PCL Self-Assembly Micelles for Colorectal Cancer Therapy. [10]Synthesis and Biological Evaluation of Novel 4-(4-Formamidophenylamino)-N-methylpicolinamide Derivatives as Potential Antitumor Agents.